← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. GCTK
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

GCTK logoGlucoTrack, Inc. (GCTK) P/E Ratio History

Historical price-to-earnings valuation from 2026 to 2026

Current P/E
0.0
N/A
5Y Avg P/E
N/A
PE Percentile
N/A
PEG Ratio
N/A
N/A
TTM EPS$-54.14
Price$0.86
5Y PE RangeN/A
Earnings Yield100.00%

Loading P/E history...

GCTK Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
0.0vsN/A
N/A
vs. Healthcare
0.0vs22.3
-100%
Below Sector
vs. S&P 500
0.0vs25.1
-100%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 259% EPS growth (1Y)

P/E Ratio Analysis

As of May 8, 2026, GlucoTrack, Inc. (GCTK) trades at a price-to-earnings ratio of 0.0x, with a stock price of $0.86 and trailing twelve-month earnings per share of $-54.14.

Compared to the Healthcare sector median P/E of 22.3x, GCTK trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

Relative to the broader market, GCTK trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GCTK DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

GCTK P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
DXCM logoDXCMDexCom, Inc.
$24B29.12.78+47%
PODD logoPODDInsulet Corporation
$11B46.10.45-40%
ABT logoABTAbbott Laboratories
$151B11.40.38Best+134%
LMAT logoLMATLeMaitre Vascular, Inc.
$2B42.82.21+31%
INVA logoINVAInnoviva, Inc.
$2B6.9Lowest0.67+817%Best
NVO logoNVONovo Nordisk A/S
$203B12.70.61+2%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

See GCTK's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is GCTK Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare GCTK vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

GCTK — Frequently Asked Questions

Quick answers to the most common questions about buying GCTK stock.

Is GCTK stock overvalued or undervalued?

GCTK current P/E: 0.0x. 5-year average P/E: N/A. Percentile: N/A.

How does GCTK's valuation compare to peers?

GlucoTrack, Inc. P/E of 0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.

What is GCTK's PEG ratio?

GCTK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

GCTK P/E Ratio History

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.